Document Detail


GABAA-benzodiazepine-chloride receptor-targeted therapy for tinnitus control: preliminary report.
MedLine Citation:
PMID:  14763233     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Our goal was to attempt to establish neuropharmacological tinnitus control (i.e., relief) with medication directed to restoration of a deficiency in the gamma-aminobutyric acid-benzodiazepine-chloride receptor in tinnitus patients with a diagnosis of a predominantly central type tinnitus. Thirty tinnitus patients completed a medical audiological tinnitus patient protocol and brain magnetic resonance imaging and single-photon emission computed tomography of brain. Treatment with GABAergic and benzodiazepine medication continued for 4-6 weeks. A maintenance dose was continued when tinnitus control was positive. Intake and outcome questionnaires were completed. Of 30 patients, 21 completed the trial (70%). Tinnitus control lasting from 4-6 weeks to 3 years was reported by 19 of the 21 (90%). The trial was not completed by 9 of the 30 (30%). No patient experienced an increase in tinnitus intensity or annoyance. Sequential brain single-photon emission computed tomography in 10 patients revealed objective evidence of increased brain perfusion. Patients with a predominantly central type tinnitus experience significant tinnitus control with medication directed to the gamma-aminobutyric acid-benzodiazepine-chloride receptor.
Authors:
Abraham Shulman; Arnold M Strashun; Barbara A Goldstein
Related Documents :
17457443 - Hearing threshold in patients with chronic renal failure.
8071153 - Monaural sound localization: acute versus chronic unilateral impairment.
11068853 - Copper, ceruloplasmin and superoxide dismutase (sod) in amyotrophic lateral sclerosis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The international tinnitus journal     Volume:  8     ISSN:  0946-5448     ISO Abbreviation:  Int Tinnitus J     Publication Date:  2002  
Date Detail:
Created Date:  2004-02-06     Completed Date:  2004-02-27     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  9612993     Medline TA:  Int Tinnitus J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  30-6     Citation Subset:  IM    
Affiliation:
Martha Entenmann Tinnitus Research Center, Health Science Center at Brooklyn, State University of New York, Box 1239, 450 Clarkson Avenue, Brooklyn, NY 11203, USA. metrc@inch.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetates / administration & dosage,  therapeutic use
Adult
Aged
Aged, 80 and over
Amines*
Benzodiazepines / administration & dosage,  pharmacology,  therapeutic use*
Chloride Channels / drug effects*,  metabolism
Clonazepam / administration & dosage,  therapeutic use
Cyclohexanecarboxylic Acids*
Female
GABA Agents / administration & dosage,  pharmacology,  therapeutic use*
Humans
Instillation, Drug
Magnetic Resonance Imaging
Male
Middle Aged
Questionnaires
Receptors, GABA / drug effects*,  physiology
Receptors, GABA-A / drug effects,  physiology
Tinnitus / drug therapy*,  psychology
Tomography, Emission-Computed, Single-Photon
gamma-Aminobutyric Acid*
Chemical
Reg. No./Substance:
0/Acetates; 0/Amines; 0/Chloride Channels; 0/Cyclohexanecarboxylic Acids; 0/GABA Agents; 0/Receptors, GABA; 0/Receptors, GABA-A; 12794-10-4/Benzodiazepines; 1622-61-3/Clonazepam; 56-12-2/gamma-Aminobutyric Acid; 6CW7F3G59X/gabapentin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The early kinetics of gentamicin uptake into the inner ear.
Next Document:  Characteristics of tinnitus and etiology of associated hearing loss: a study of 123 patients.